$110,000 of CINTAS CORPORATION lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Advice and counsel regarding federal regulation impacting the apparel industry. Support for defibrillation access, including H.R. 2370/S. 1024, Access to AEDs Act. Advice and counsel regarding workplace safety regulation. Advice and counsel on corporate tax reform."
You can find more data on corporate lobbying on Quiver Quantitative.
CTAS Congressional Stock Trading
Members of Congress have traded $CTAS stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CTAS stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 1 purchase worth up to $100,000 on 04/07 and 2 sales worth up to $150,000 on 05/12, 05/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
CTAS Insider Trading Activity
CTAS insiders have traded $CTAS stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CTAS stock by insiders over the last 6 months:
- RONALD W TYSOE sold 8,521 shares for an estimated $1,780,548
- JIM ROZAKIS (Executive Vice President & COO) sold 2,000 shares for an estimated $380,740
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CTAS Hedge Fund Activity
We have seen 710 institutional investors add shares of CTAS stock to their portfolio, and 589 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ACADIAN ASSET MANAGEMENT LLC removed 1,075,798 shares (-42.9%) from their portfolio in Q1 2025, for an estimated $221,108,762
- IMPAX ASSET MANAGEMENT GROUP PLC removed 905,991 shares (-48.8%) from their portfolio in Q1 2025, for an estimated $186,208,330
- WINSLOW CAPITAL MANAGEMENT, LLC added 850,880 shares (+79.3%) to their portfolio in Q1 2025, for an estimated $174,881,366
- VOYA INVESTMENT MANAGEMENT LLC added 715,570 shares (+516.8%) to their portfolio in Q1 2025, for an estimated $147,071,102
- INVESCO LTD. removed 702,599 shares (-13.7%) from their portfolio in Q1 2025, for an estimated $144,405,172
- HRT FINANCIAL LP removed 629,983 shares (-92.9%) from their portfolio in Q1 2025, for an estimated $129,480,405
- CAISSE DE DEPOT ET PLACEMENT DU QUEBEC added 573,151 shares (+169.7%) to their portfolio in Q1 2025, for an estimated $117,799,725
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CTAS Analyst Ratings
Wall Street analysts have issued reports on $CTAS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 07/02/2025
- B of A Securities issued a "Buy" rating on 04/10/2025
- UBS issued a "Buy" rating on 03/27/2025
- Truist Securities issued a "Buy" rating on 03/27/2025
- Citigroup issued a "Sell" rating on 02/24/2025
To track analyst ratings and price targets for CTAS, check out Quiver Quantitative's $CTAS forecast page.
CTAS Price Targets
Multiple analysts have issued price targets for $CTAS recently. We have seen 10 analysts offer price targets for $CTAS in the last 6 months, with a median target of $228.5.
Here are some recent targets:
- George Tong from Goldman Sachs set a target price of $257.0 on 07/02/2025
- Jason Haas from Wells Fargo set a target price of $221.0 on 07/01/2025
- Ashish Sabadra from RBC Capital set a target price of $240.0 on 06/09/2025
- Joshua Dennerlein from B of A Securities set a target price of $250.0 on 04/10/2025
- Andrew Wittmann from Baird set a target price of $227.0 on 03/27/2025
- Toni Kaplan from Morgan Stanley set a target price of $213.0 on 03/27/2025
- Joshua Chan from UBS set a target price of $240.0 on 03/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
